Grifols signs an agreement with Gambro Renal Products (GRP) for MARS® in Spain and Portugal

**Barcelona, May 10th 2008.**— Grifols, in line with its commitment to offer the most advanced products and services to health professionals, has signed a distribution agreement for MARS® (liver support therapy) for Spain and Portugal.

Grifols began distributing MARS® in 2003 in certain countries in Latin America through an agreement with Teraklin AG. The renewal of the agreement in 2006 after Teraklin was acquired by Gambro is recognition of Grifols’ work to introduce this therapy. Now Gambro is extending its contract with Grifols as a trusted partner for the distribution of its MARS® liver support system. Through its affiliate, Movaco, Grifols will distribute this system to hepatology and intensive care units in hospitals in Spain and Portugal.

MARS® liver support therapy (Molecular Adsorbent Recirculating System) is based on dialysis with albumin. Substances which bind to albumin accumulate during liver failure and are eliminated through hemodialysis against an albumin solution. The WHO calculates that around 12 million people worldwide suffer from severe liver disease. It is estimated that at least 70,000 people could potentially benefit from liver support therapy per year. In the past, there were no systems able to resolve the complications of liver failure while also being suitable for routine clinical practice. In hemodialysis, the artificial kidney is unable to eliminate toxins bound to proteins which are normally metabolized in the liver.

MARS® is used in more than 30 countries as a therapy indicated in cases of acute failure in chronic hepatopathy caused by chronic viral hepatitis, cirrhosis, alcoholic hepatopathy, acute liver failure due to varied etiology (ischemic hepatitis, viral hepatitis, liver failure caused by medication), primary failure and primary dysfunction of a transplant, liver failure or dysfunction due to liver surgery, secondary liver failure and untreatable pruritus in chronic cholestasis. MARS therapy is a new combination of kidney and liver dialysis which stabilizes the liver function of the patient until they recover or receive a transplant.

**About Gambro Renal Products (GRP)**

Gambro Renal Products belongs to the Gambro Group. GRP is a global leader in developing and supplying products, therapies and services for dialysis in the hospital and at home, as well as blood purification in Intensive Care units.

With more than 7,000 employees, production facilities in 11 countries, sales in more than 100, and sales subsidiaries in more than 40, GRP designs and delivers complete solutions – including products, therapies and services – to improve the treatment of renal and intensive care patients.

For decades, GRP has led the market in renal care development and has been first to market with many innovations. By designing and delivering complete solutions to dialysis clinics and intensive care units, GRP offers not just improved treatment quality, but also improved efficiency.
About Grifols

Grifols is a holding company specialized in the hospital pharmaceutical sector and is present in more than 90 countries. Since May 2006, the company has been listed on the Spanish Continuous Market and forms part of the Ibex-35. Currently it is the first company in the European sector in plasma derivatives and the fourth in production worldwide. In upcoming years, the company will strengthen its leadership in the industry as a vertically integrated company, thanks to recent investments and those which will be carried out in 2008-2012, representing 400 million euros. In terms of raw materials, Grifols has ensured its plasma supply with 77 plasmapheresis centers in the United States and in terms of fractionation, its plants in Barcelona (Spain) and Los Angeles (United States) will allow the company to respond to the growing market demand. Nevertheless, the company is preparing for sustained growth in the following 8-10 years and has launched an ambitious investment plan.

Grifols’ activities are focused on satisfying health professionals’ requirements, within the therapeutical applications environment, pharmaceutical, diagnostic and blood banks. For over 60 years, Grifols has produced and distributed products meeting high security, quality and efficacy standards which contribute to improve human health.